microRNA 92a-2 (MIR92A2)

microRNA 92a-2 (MIR92A2) is a small, non-coding RNA that pairs with mRNA to modulate gene expression post-transcriptionally, primarily through sequence-dependent inhibition or degradation of target transcripts[2][4]. It belongs to the miR-17~92 cluster—a group known for strong roles in cell proliferation, differentiation, and apoptosis[3][4]. MIR92A2 is implicated in the development of several human cancers, including colorectal and blood cancers, where its aberrant expression correlates with tumorigenesis, progression, and poor clinical outcomes[1][2][4]. In the kidney, MIR92A2 promotes crescent formation and loss of podocyte quiescence, contributing to rapidly progressive glomerulonephritis, and its inhibition can ameliorate disease by restoring expression of negative regulators of the cell cycle like p57 Kip2[3]. MIR92A2 is also being evaluated as a minimally invasive serum or plasma biomarker for early cancer detection and prognosis[1][4].\n\nNo FDA-approved drugs directly target MIR92A2, but antisense oligonucleotide inhibitors (anti-miR-92a) have shown efficacy in preclinical disease models[3]. Its clinical utility as a biomarker is currently being studied, especially in cancer and kidney disease[1][3].\n\nMIR92A2’s broad regulatory effects and potential associations with diverse pathologies make it an attractive therapeutic and diagnostic target, though significant challenges remain regarding specificity, safety, and application across multiple tissues[1][3].

Other names

hsa-mir-92-2hsa-mir-92a-2MIRN92-2MIRN92A-2MIRN92A2mir-92a-2microRNA 92-2

microRNA inhibition (anti-miR-92a agents block miR-92a action, leading to upregulation of target mRNA such as CDK inhibitor p57 Kip2 and preservation of podocyte function). RNA interference (regulation of target mRNA translation and stability by incorporation into RISC complex).